biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON
CG Oncology
CG Oncology is a biotech organization headquartered in Dallas, USA. It trades on NYSE under ticker CGON. Primary therapeutic focus areas include Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carci
Dallas, USA HQ
2010 Founded
187 Employees
Public company Type
CGON · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dallas, USA
- Founded
- 2010
- Employees
- 187
- Programs
- 8
- Drugs
- 1
- Patents
- 5
Cretostimogene Grenadenorepvec
Phase 2 · small molecule · High-Risk Non-Muscle-Invasive Bladder Cancer
Cretostimogene Grenadenorepvec for High-Risk Non-Muscle-Invasive Bladder Cancer is a Phase 2 program (small_molecule) at CG Oncology with 1 ClinicalTrials.gov record(s).
Internal code CORE-008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CG Oncology
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Status
- active
- Trials
- 1